BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu H, Fu X, Zhai Y, Gao S, Yang X, Zhai G. Development of Effective Tumor Vaccine Strategies Based on Immune Response Cascade Reactions. Adv Healthc Mater 2021;10:e2100299. [PMID: 34021717 DOI: 10.1002/adhm.202100299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Q, Wang Z, Sun X, Jiang Q, Sun B, He Z, Zhang S, Luo C, Sun J. Lymph node-targeting nanovaccines for cancer immunotherapy. J Control Release 2022;351:102-22. [PMID: 36115556 DOI: 10.1016/j.jconrel.2022.09.015] [Reference Citation Analysis]
2 Li J, Liu F, Chen Y, Zhang D. Dynamic Analysis of a Model on Tumor-Immune System with Regulation of PD-1/PD-L1 and Stimulation Delay of Tumor Antigen. Qual Theory Dyn Syst 2022;21. [DOI: 10.1007/s12346-022-00627-5] [Reference Citation Analysis]
3 Liu X, Liu Y, Li X, Huang J, Guo X, Zhang J, Luo Z, Shi Y, Jiang M, Qin B, Du Y, Luo L, You J. ER-Targeting PDT Converts Tumors into In Situ Therapeutic Tumor Vaccines. ACS Nano 2022. [PMID: 35713245 DOI: 10.1021/acsnano.2c01669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen X, Zhang Y, Fu Y. The Critical Role of Toll-like Receptor-mediated Signaling in Cancer Immunotherapy. Medicine in Drug Discovery 2022. [DOI: 10.1016/j.medidd.2022.100122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Guo Y, Wang Z, Shi X, Shen M. Engineered cancer cell membranes: An emerging agent for efficient cancer theranostics. Exploration 2022;2:20210171. [DOI: 10.1002/exp.20210171] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]